Abstract
Aim: To analyze the association of NKX2.5 gene with congenital heart disease (CHD), and to determine if the variants rs703752, rs3729753 and rs2277923 increase the risk for developing CHD. Materials & methods: PubMed, EBSCO and Web of Science databases were screened to identify eligible studies. Through a comprehensive meta-analysis software, the association between NKX2.5 gene variants and susceptibility of CHD was calculated by pooled odd ratio (ORs) and 95% CI. Results: We observed that the allelic model of rs703752 and rs2277923 increased the risk in the overall population: OR = 1.24; 95% CI: 1.00–1.55; Z p-value = 0.049; OR = 1.18; 95% CI: 0.01–1.37; Z p-value = 0.036; respectively. Conclusion: Our results suggested that the rs703752 and rs2277923 polymorphisms of the NKX2.5 gene are associated with CHD.
Author contributions
TB González-Castro, CA Tovilla-Zárate, JM Rodríguez-Pérez, N Pérez-Hernández conception and design of the systematic review and meta-analysis; JM Rodríguez-Pérez and N Pérez-Hernández; ML López-Narvaez, IE Juárez-Rojop, J Calderón-Colmenero, JP Sandoval, JA García-Montes, R Blachman-Braun and RG Castillo-Avila were involved in the acquisition and analysis of the data; TB González-Castro, CA Tovilla-Zárate, E García-Flores, BG Cazarín-Santos, VM Borgonio-Cuadra, R Posadas-Sánchez, G Vargas-Alarcón, JM Rodríguez-Pérez and N Pérez-Hernández interpreted the results and drafted this paper. All authors provided critical revisions of the meta-analysis and approved submission of the final manuscript all authors.
Acknowledgements
The researchers are grateful with Universidad Juárez Autónoma de Tabasco, Departments of Pediatric Cardiology and Molecular Biology from Instituto Nacional de Cardiología Ignacio Chávez for all support received for the present work.
Financial & competing interests disclosure
The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.